Novo Nordisk has officially launched it’s weight-loss drug Wegovy in Argentina, making it available to patients at La Rural, a prominent healthcare and exhibition center in Buenos Aires. The launch, occurring on 2025/10/12, marks a notable expansion of access to the medication outside of North America and Europe.
The introduction of Wegovy to the Argentine market addresses a growing need for effective obesity treatments within the country, where rates of overweight and obesity are rising. Wegovy, a weekly injectable medication containing semaglutide, works by mimicking a hormone that regulates appetite and food intake, potentially aiding patients in achieving significant weight loss and reducing the risk of weight-related health complications.This launch follows recent approvals by Argentine health authorities and positions Novo Nordisk to serve a substantial patient population seeking innovative weight management solutions.
Juliana Moculsky, a key speaker at the launch event, highlighted the importance of thorough obesity care, emphasizing that Wegovy is intended to be used alongside lifestyle interventions like diet and exercise.The drug’s availability at La Rural provides a centralized location for healthcare professionals to prescribe and patients to access the treatment.
